ClinicalTrials.gg
CompletedNCT01867307Updated May 11, 2017Results posted

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

A Phase 2 interventional study of Empagliflozin and BI 10773 in Diabetes Mellitus, Type 2 and Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-11.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
97th of 130
39 · median 79
Started
2013
with 3 others
Phase 2
17 of 130
none open now
Registered
28th of 130
by date
Lead sponsor
37 of 130
Boehringer Ingelheim

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 97th largest by enrollment, is one of 4 that started in 2013, is one of 17 in phase 2, and was the 28th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Single center, 14-day, open-label trial to examine the effect of 25 mg q.d. empagliflozin on kinetics of renal glucose reabsorption in patients diagnosed with type 2 diabetes mellitus and healthy controls

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Healthy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. T2DM patients and healthy controls aged =18 to \<70 at Visit 1.
  2. Patients diagnosed with T2DM according to the American Diabetes Association criteria prior to who are drug-naïve
  3. T2DM patients on a stable dose of allowed concomitant medications (as determined by investigator) for 30 days prior to entering the study.
  4. T2DM patients with between >7 and \<10.0% (>53 mmol/mol and \<86 mmol/mol) at Visit

Exclusion criteria

Exclusion criteria:

  1. Patients with type 1 diabetes mellitus.
  2. Patients with uncontrolled hyperglycemia with a fasting plasma glucose level greater than 240 mg/dl after an overnight fast.
  3. Patients with a history of heart disease (New York Heart Classification greater than class 3; more than non-specific ST-T wave changes on the ), peripheral vascular disease (history of claudication), or pulmonary disease as determined by investigator.
  4. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Healthy Controls

    healthy controls

    Drug: BI 10773

  • Experimental
    Patients

    patients with type 2 diabetes mellitus

    Drug: Empagliflozin

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14)

    Change from baseline of renal tubular maximum reabsorptive capacity for glucose (TmG) at end of empagliflozin treatment (Day 14). Per-protocol set (PPS): PPS consisted of all subjects and patients in the TS who completed the treatment day 14 clamping study without any relevant deviations either in their treatment regimen or in the performance and timing of the measurements.

    Time frame: Baseline and Day 14

07

Results

Posted May 11, 2017

Participant flow

39 subjects were enrolled in the trial; 37 subjects were treated with the trial treatment, 2 subjects were not treated with the trial treatment (1 subject from type 2 diabetes mellitus (T2DM) patients arm and 1 subject from the Healthy subjects arm were not treated)

Participant flow — Overall Study
MilestoneT2DM PatientsHealthy Subjects
Started1819
Completed1516
Not completed33
Withdrew: Protocol violation20
Withdrew: Other adverse event13

Outcome measures

PrimaryChange From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14)

Change from baseline of renal tubular maximum reabsorptive capacity for glucose (TmG) at end of empagliflozin treatment (Day 14). Per-protocol set (PPS): PPS consisted of all subjects and patients in the TS who completed the treatment day 14 clamping study without any relevant deviations either in their treatment regimen or in the performance and timing of the measurements.

Time frame:
Baseline and Day 14
Reported as:
Mean · (milligram / minute/ 1.73 square meters)
Change From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14)
(milligram / minute/ 1.73 square meters)T2DM PatientsHealthy Subjects
Change From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14)-321.7 ± 214.9-256.9 ± 100.0
Statistical analysis
  • T2DM Patients · Paired t- test · p = <0.0001 (P-value is from a paired t-test.) · Median difference (final values): -220.0 · 95% CI -440.6 to -202.7Difference calculated as (Day 14 - baseline) values
  • Healthy Subjects · Paired t-test · p = <0.0001 (P-value is from a paired t-test) · Median difference (final values): -234.0 · 95% CI -312.3 to -201.5Difference calculated as (Day 14 - baseline) values

Adverse events

Collected over From first drug administration through the residual effect and/or follow-up period, up to 21 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T2DM Patients—0/18 (0%)14/18 (77.8%)
Healthy Subjects—0/19 (0%)16/19 (84.2%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventT2DM PatientsHealthy Subjects
PollakiuriaRenal and urinary disorders9/186/19
Muscle spasmsMusculoskeletal and connective tissue disorders1/187/19
Dry mouthGastrointestinal disorders4/180/19
ErythemaSkin and subcutaneous tissue disorders2/184/19
VomitingGastrointestinal disorders0/183/19
HeadacheNervous system disorders0/182/19
PhlebitisVascular disorders0/182/19
NauseaGastrointestinal disorders1/182/19
PainGeneral disorders1/182/19
SwellingGeneral disorders1/182/19

Baseline characteristics

The treated set (TS) consisted of all subjects and patients who were treated with at least one dose of empagliflozin.

Age, Continuous
Age, Continuous(years)T2DM PatientsHealthy SubjectsTotal
Mean55.1 ± 5.556.7 ± 6.355.9 ± 5.9
Sex: Female, Male
Sex: Female, Male(Participants)T2DM PatientsHealthy SubjectsTotal
Female5712
Male131225
08

Study locations

1 site
  • Boehringer Ingelheim Investigational Site
    San Antonio, Texas, United States
09

References and documents

Publications

  • Abdul-Ghani M, Al Jobori H, Daniele G, Adams J, Cersosimo E, Triplitt C, DeFronzo RA. Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves beta-Cell Function in Subjects With Impaired Fasting Glucose. Diabetes. 2017 Sep;66(9):2495-2502. doi: 10.2337/db17-0055. Epub 2017 Jun 13. PubMed 28611037 ↗
  • Al-Jobori H, Daniele G, Cersosimo E, Triplitt C, Mehta R, Norton L, DeFronzo RA, Abdul-Ghani M. Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes. Diabetes. 2017 Jul;66(7):1999-2006. doi: 10.2337/db17-0100. Epub 2017 Apr 20. PubMed 28428225 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 1 year 7 months after primary completion. A results delay was requested in Aug 2016.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2013
First posted
Jun 4, 2013
Start
Jun 2013
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results delay requested
Aug 23, 2016
Results first posted
May 11, 2017
Last update
May 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01867307
Responsible party
Sponsor
First posted
Jun 4, 2013
Start date
Jun 2013
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
May 11, 2017
Last update
May 11, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion